Page last updated: 2024-11-12
neanthine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
neanthine: structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 12521357 |
SCHEMBL ID | 164277 |
MeSH ID | M0052225 |
Synonyms (40)
Synonym |
---|
methoxyethyl mercuric chloride |
emisan 6 |
beta-methoxyethylmercury chloride |
atiran |
higosan |
vegoll |
tafasan 6w |
mercury, chloro(2-methoxyethyl)- |
chloro(2-methoxyethyl)mercury |
emisan |
2-methoxyethylmercuric chloride |
(beta-methoxyethyl)mercuric chloride |
brn 4123443 |
tafasan |
2-methoxyethylmerkurichlorid [czech] |
tayssato |
merchlorate |
methoxyaethylquecksilberchlorid [german] |
methoxyethylmercury chloride |
aretan 6 |
memc |
agallolat |
ccris 5835 |
gramisan |
neanthine |
agallo forte |
ceresan universal wet |
ceranit 6 |
aretan |
einecs 204-659-7 |
sedresan |
2-methoxyethylmercury chloride |
123-88-6 |
2-methoxyethylmerkurichlorid |
unii-8j3u131744 |
methoxyaethylquecksilberchlorid |
SCHEMBL164277 |
methoxyethylmercuric chloride |
(2-methoxyethyl)mercury(ii) chloride |
2-methoxyethyl-mercury-chloride |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
"05 times more toxic than mercuric chloride (HgCl2) and emisan 6 (methoxyethyl mercury chloride), respectively, for 96 hr." | ( Toxic effects of three mercurial compounds on survival, and histology of the kidney of the catfish Clarias batrachus (L.). Joy, KP; Kirubagaran, R, 1988) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (15)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 12 (80.00) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 2 (13.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (6.25%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (93.75%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |